Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 398th consecutive...
- Abbott, Real Madrid and the Real Madrid Foundation launch 'Beat Malnutrition' campaign as part of a sustained collaboration urging communities to...
Abbott, Real Madrid and the Real Madrid Foundation launch 'Beat Malnutrition' campaign as part of a sustained collaboration urging communities to...
New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott's CardioMEMS™ HF System ...
Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a...
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter, Sensor...
Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance,...
FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic...
Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and...
Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an...
Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life...
Abbott is joining the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which will use data science to predict, track and control...
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023. First-quarter GAAP diluted EPS of $0.75 and adjusted ...
The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day...
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated...
Abbott will announce its first-quarter 2023 financial results on Wednesday, April 19, 2023, before the market opens. The announcement will be...
A Abbott (NYSE: ABT) anuncia a recente aprovação da ANVISA (Agência Nacional de Vigilância Sanitária) para a geração mais recente do seu sistema para ...
The Concussion Awareness Now campaign raises awareness both about the common, everyday ways concussions most often happen and the importance of...
Os autotestes podem ajudar a superar algumas barreiras como o estigma associado ao teste de HIV, além de ampliar o diagnóstico e o acesso aos...
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration clearance for what will be the first commercially available laboratory traumatic...
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3...
New five-year data presented at American College of Cardiology Scientific Sessions (ACC.23) and simultaneously published in The New England Journal...
Abbott (NYSE: ABT) today announced late-breaking data for the TriClip™ transcatheter edge-to-edge repair (TEER) system, a first-of-its-kind minimally ...
New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.